Summit Therapeutics and Akeso said Wednesday their bispecific PD-1/VEGF antibody ivonescimab (SMT112/AK112) scored yet another Chinese Phase III win, this time demonstrating an overall survival (OS) benefit in front-line advanced biliary tract cancer (BTC) — its first pivotal success beyond four positive non–small-cell lung cancer (NSCLC) readouts. "The breakthrough clinical value of ivonescimab is now expanding from lung cancer to a broader range of solid tumours," said Akeso CEO Michelle Xia.

The FDA has approved Takeda’s Mimrylo (rusfertide) for polycythemia vera, introducing a new mechanism of action to the nonmalignant rare blood cancer and handing CEO Julie Kim another major regulatory win since taking the helm. A form of myeloproliferative neoplasm, polycythemia vera (PV) causes the bone marrow to make too many red blood cells, which can result in life-threatening cardiovascular events, such as stroke and heart attack. Mimrylo offers a new approach to curtailing the overproduc

Teva has agreed to bid up to $125 million for BioXcel Therapeutics' neuroscience assets, including marketed agitation treatment Igalmi (dexmedetomidine), as the struggling biotech enters Chapter 11 bankruptcy. Teva will serve as the stalking-horse bidder in a court-supervised auction for substantially all of BioXcel's assets. Under the agreement, Teva would pay $57.5 million upfront for worldwide rights to the assets, with up to another $67.5 million in contingent payments. The latter includes

Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and global commercialization DUPAC, one of the DualityBio's four proprietary ADC technology platforms, comprises multiple payloads with novel mechanism of action designed to address resistance to the payload classes underlying currently approved ADCs DualityBio to receive a US$45 million upfront payment, more than US$1

Financing supports advancement of AHB-137 toward potential commercialization, including its Phase 3 registrational program and commercialization readiness Proceeds will also accelerate AHB-171 and next-generation combination approaches designed to advance functional cure for chronic hepatitis B Series C brings AusperBio's total capital raised to $360 million since 2024 Aug. 27, 2026 -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively "AusperBio" or the "Company"), a n

ProFound Therapeutics has received up to $35 million in backing from the Gates Foundation, including an initial $20 million, to use its proteomics and AI platform to identify drug targets and biomarkers for preeclampsia and eclampsia. The Flagship Pioneering-founded biotech will analyse proteins found in the placenta and serum of women with the pregnancy complications. "The expanded proteome represents a vast and largely untapped resource for identifying novel protein drugs, drug targets," said

Designation supports the global development of RTX-117 and may provide potential future access to a transferable Priority Review Voucher, subject to approval and applicable requirements Aug. 26, 2026 -- ReviR Therapeutics, a clinical-stage biotechnology company advancing small-molecule therapies through the integration of artificial intelligence and RNA biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RTX-117, the

SK Biopharmaceuticals has strengthened its epilepsy offering by paying $350 million upfront to help speed Biohaven’s Kv7 ion channel activator on its way to market. Biohaven is currently evaluating the daily oral therapy, called opakalim or BHV-7000, in a phase 2/3 study of patients with focal epilepsy. A topline readout is expected later this year. Rather than wait for the results, SK has agreed to hand over the upfront cash—along with another $50 million next year—for the worldwide license t

NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan 26 August 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TS

The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care (durvalumab monotherapy or nivolumab monotherapy or enfortumab vedotin plus pembrolizumab) as an adjuvant treatment (after surgery) in patients with muscle invasive urothelial cancer (MIUC) at high risk of recurrence following radical surgical resection with or without prior neoadjuvant therapy. Datrow